Bruton’s tyrosine kinase (BTK) inhibition is revolutionising the treatment landscape for chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL), with zanubrutinib emerging as a leading option for treatment-naïve patients. The Phase 3 SEQUOIA study has provided compelling evidence regarding the efficacy and safety of zanubrutinib, offering insights into its long-term impact on disease management.
- By maintaining continuous BTK inhibition, zanubrutinib downregulates pathways like NF-κB, which correlates with reduced proliferation of malignant clones in CLL and SLL.
- Reports suggest that progression-free survival rates maintain a significant advantage for zanubrutinib, showcasing its potential for long-term clinical benefits.
- Individualised risk assessments are critical, especially for patients with pre-existing conditions that could complicate treatment.
SEQUOIA Study Highlights
The SEQUOIA study, a pivotal Phase 3 randomised open-label trial, compared zanubrutinib with the traditional combination of bendamustine plus rituximab (BR) in patients with untreated CLL/SLL who did not possess 17p deletion. The primary outcome was progression-free survival (PFS), with additional parameters including overall response rate (ORR), overall survival (OS), and safety, particularly in genetically defined subgroups.
Extended follow-up data from the trial presented at various hematology congresses, including the annual ASH meetings, has allowed clinicians to assess the durability of treatment responses and long-term safety concerns associated with BTK therapies.
Mechanisms of Action in BTK Inhibition
Zanubrutinib acts as a specific and irreversible BTK inhibitor, targeting B-cell receptor signalling pathways critical for the survival of B-cell malignancies. Compared to earlier-generation BTK inhibitors, zanubrutinib offers improved pharmacokinetic selectivity, potentially minimising off-target effects.
By maintaining continuous BTK inhibition, zanubrutinib downregulates pathways like NF-κB, which correlates with reduced proliferation of malignant clones in CLL and SLL.
Long-Term Efficacy Observed
Recent analyses from the SEQUOIA study indicate that sustained disease control is achievable with zanubrutinib over multi-year follow-ups in treatment-naïve populations. The six-year follow-up data highlights the continued superiority of BTK inhibition over traditional chemoimmunotherapy regimens.
Reports suggest that progression-free survival rates maintain a significant advantage for zanubrutinib, showcasing its potential for long-term clinical benefits.
Safety and Tolerability Considerations
A primary concern in the long-term use of BTK inhibitors is safety. Zanubrutinib has demonstrated good tolerability, particularly when monitored for cardiovascular events, bleeding risks, and cytopenias during prolonged exposure. The SEQUOIA study indicates lower dropout rates due to adverse events compared to traditional chemotherapy and immunotherapy options.
Individualised risk assessments are critical, especially for patients with pre-existing conditions that could complicate treatment.
Implications for Clinical Practice
For hematologists, the long-term findings from the SEQUOIA study are instrumental in shaping treatment decisions between ongoing BTK inhibition and time-limited chemoimmunotherapy approaches. Factors influencing these decisions include the depth and duration of remission achievable with continuous BTK inhibition, the long-term safety profile, patient co-morbidities, and quality-of-life considerations.
Positioning of Zanubrutinib in CLL/SLL Treatment
The shift towards targeted oral therapies, such as BTK and BCL-2 inhibitors, has transformed CLL/SLL treatment protocols. The SEQUOIA study’s long-term data serves as a benchmark against older chemoimmunotherapy standards and highlights the evolving nature of combination treatment approaches.
Continuous reporting from clinical trials and real-world evidence will further refine best practices in treatment sequencing, optimal duration for BTK inhibition, and the development of fixed-duration regimens.
